Friday Mar 7
New Market Report: BioMarin Pharmaceutical Inc. (BMRN) - Financial and Strategic SWOT Analysis Review
The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats.
Trending on the Topix Network
Tue Mar 04, 2014
The Business Journal
North Bay groups collaborating on building biotech sector
Biomedical business have been proliferating in Marin County - Novato, in particular - for the past decade, significantly boosting the local economy, and growth is something business boosters from around the North Bay are actively trying to replicate, according to a new report.
BioMarin Announces Public Offering of Common Stock
BioMarin Pharmaceutical Inc. announced today an offering, subject to market and other conditions, of 1,500,000 shares of its common stock in an underwritten public offering.
BioMarin Pharmaceutical Inc. To Present At The Global Healthcare Conference In Miami
BioMarin Pharmaceutical Inc. , a global leader in the development and commercialization of therapies for rare genetic diseases, today announced that Dan Oppenheimer, Group Vice President, Development and Portfolio Strategy will present at the Barclays Global Healthcare Conference on March 12th at 9:00am ET.
Audentes Therapeutics Announces Significant Additions to Leadership Team
Audentes Therapeutics, Inc., a biotechnology company dedicated to the development and commercialization of innovative treatments for rare diseases using gene therapy technology, has announced the expansion of its leadership team, including the appointment of Suyash Prasad, M.D. as Senior Vice President and Chief Medical Officer.
Mon Mar 03, 2014
The Motley Fool
BioMarin Pharmaceutical, Inc.: Is This Orphan Drug Specialist Overvalued?
It's not easy to develop treatments for rare diseases, but it is hard to argue with the rewards.
Sun Mar 02, 2014
Customer Interaction Solutions
Novato launches effort to woo biotech firms [The Marin Independent Journal, Novato, Calif. :: ]
Via Acquire Media NewsEdge) March 02--A cure for cancer, AIDS, or the heartbreak of psoriasis just might be discovered in Novato if plans underway to attract more biotech firms to the city come to fruition.
Sat Mar 01, 2014
BioMarin Pharmaceutical Price Target Raised to $95.00 at Cowen and Company
Cowen and Company's target price points to a potential upside of 17.28% from the stock's previous close.
Thu Feb 27, 2014
Amgen, BioMarin Lead Biotech Short Interest Trend
Among the leading biotech and emerging pharmaceutical companies, Amgen , Biogen Idec and BioMarin Pharmaceutical saw the largest percentage increases in short interest between the January 31 and February 15 settlement dates.
BioMarin Pharmaceutical Inc. Announces Fourth Quarter and Full Year 2013 Financial Results
BioMarin Pharmaceutical Inc. today announced financial results for the fourth quarter and full year 2013.
Wed Feb 26, 2014
Biomarin Pharmaceutical Inc - 10-K - Management's Discussion and...
The following discussion of our financial condition and results of operations should be read in conjunction with our Consolidated Financial Statements and notes to those statements included elsewhere in this Annual Report on Form 10-K.
The Business Journal
BioMarin loss expands in 2013 on rampup for key products
BioMarin Pharmaceutical Inc. on Wednesday reported its fourth-quarter and full-year net losses expanded nearly 17 percent and 54 percent, respectively, attributed to more research-and-development and marketing expenses for key treatments for rare diseases.
Tue Feb 25, 2014
BioMarin Pharmaceutical Inc. To Present At The Healthcare Conference In Boston
BioMarin Pharmaceutical Inc. , a global leader in the development and commercialization of therapies for rare genetic diseases, today announced that Dan Maher, Senior Vice President, Product Development will present at the Cowen and Company 34th Annual Healthcare Conference on March 4th at 11:20am ET.
Mon Feb 24, 2014
The Business Journal
Shares of BioMarin shoot up after FDA approval
Investors in BioMarin Pharmaceutical have been bullish about the recent U.S. Food and Drug Administration approval for Vimizim, the first approved treatment for the rare disease Morquio A syndrome.
Sun Feb 23, 2014
The Motley Fool
BioMarin Pharmaceutical Inc: The Future Looks Bright
It started with the U.S. Food and Drug Administration, or FDA, officially approving the company's enzyme replacement therapy for Morquio A syndrome called Vimizm.
Fri Feb 21, 2014
BioMarin Pharmaceutical Upgraded to "Neutral" at McLean Capital Management
A number of other firms have also recently commented on BMRN. Analysts at Barclays raised their price target on shares of BioMarin Pharmaceutical from $73.00 to $76.00 in a research note on Wednesday.
FDA punches BioMarin's 'golden ticket' for speedy drug review
Annabelle Bozarth started taking Vimizim, BioMarin Pharmaceutical's enzyme replacement therapy for MPS IVA, in a Phase III clinical trial.
FDA Approves Vimizim (Elosulfase Alfa) to Treat Rare Congenital Enzyme Disorder
The FDA has approved Vimizim , the first agency-approved treatment for mucopolysaccharidosis type IVA .
Thu Feb 20, 2014
BioMarin Receives Positive Opinion From the CHMP in the European...
BioMarin Pharmaceutical Inc. announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the company's Marketing Authorization Application for VIMIZIM for the treatment of Morquio A syndrome, also called Mucopolysaccharidosis Type IVA .